非诺贝特对非酒精性脂肪性肝病合并2型糖尿病患者血脂、血管内皮功能和肝纤维化指标的影响*

doi:10.3969/j.issn.1672-5069.2020.01.015

摘要/Abstract

摘要： 目的探讨非诺贝特治疗对非酒精性脂肪性肝病(NAFLD)合并2型糖尿病(T2DM)患者血脂、血管内皮功能和肝纤维化指标的影响。方法 2017年1月～2018年5月我院收治的112例NAFLD合并T2DM患者,采用随机数字表法将患者分成两组,每组56例。指导对照组患者有氧运动和调节饮食,并接受胰岛素治疗,观察组患者在上述治疗的基础上给予非诺贝特口服治疗,观察3个月。结果在治疗结束时,观察组和对照组血TG水平分别为(1.9±0.4)mmol/L对(3.5±0.5)mmol/L, TC水平分别为(4.9±0.7)mmol/L对(6.4±0.8)mmol/L,HDLC水平分别为(1.4±0.3)mmol/L对(1.2±0.4)mmol/L,LDLC水平分别为(2.4±0.3)mmol/L对(2.6±0.4)mmol/L,差异显著(P＜0.05);血清内皮素水平分别为(49.5±3.7)pg/mL对(52.4±6.8)pg/mL,血栓素水平分别为(184.5±92.6)pg/mL对(272.7±94.8)pg/mL,前列环素水平分别为(32.1±18.4)pg/mL对(23.5±11.3)pg/mL,一氧化氮水平分别为(64.8±13.6)μmol/L对(53.2±12.4)μmol/L,差异显著(P＜0.05);血清层粘连蛋白水平分别为(170.3±65.3)μg/L对(208.7±77.4)μg/L,透明质酸水平分别为(178.6±83.4)μg/L对(233.6±81.6)μg/L,Ⅳ型胶原水平分别为(6.6±1.4)μg/L对(7.4±1.3)μg/L,Ⅲ型前胶原水平分别为(118.4±22.9)μg/L对(132.5±31.7)μg/L,差异显著(P＜0.05)。结论应用非诺贝特能有效降低非酒精性脂肪性肝病合并2型糖尿病患者血脂水平,改善血管内皮功能,降低血清肝纤维化指标,值得临床验证。

关键词: 非酒精性脂肪性肝病, 2型糖尿病, 非诺贝特, 血管内皮功能, 肝纤维化

Abstract: Objective The aim of this study was to investigate the effects of fenofibrate on blood lipids, vascular endothelial functions and liver fibrosis in patients with nonalcoholic fatty liver disease (NAFLD) and type 2 diabetes mellitus (T2DM). Methods 112 patients with NAFLD and T2MD were enrolled in our hospital between January 2017 and May 2018, and were randomly divided into two two groups, with 56 in each group. The patients in control group was treated with insulin at base of excised and diet modulation, and those in the observation were treated with fenofibrate at the basis of routine treatment in control. Results At the end of three month observation, blood TG levels were (1.9 ± 0.4) mmol/L vs. (3.5 ± 0.5) mmol/L, the TC levels were (4.9 ± 0.7) mmol/L vs. (6.4 ± 0.8), the HDLC levelswere (1.4±0.3) mmol/L vs. (1.2±0.4) mmol/L, and the LDLC levels were (2.4±0.3) mmol/L vs. (2.6±0.4) mmol/L, respectively, in the observation group and in the control group, with a significant difference (P<0.05); serum endothelin levels were (49.5±3.7) pg/mL vs. (52.4±6.8) pg/mL,the thromboxane levels were (184.5±92.6) pg/mL vs. (272.7±94.8) pg/mL, the epoprostenol were (32.1±18.4) pg/mL vs. (23.5±11.3) pg/mL, and the nitric oxide levels were (64.8±13.6) μmol/L vs. (53.2±12.4) μmol/L, respectively, with the difference being significant (P<0.05); serum laminin levels were (170.3 ± 65.3) μg/L vs. (208.7 ± 77.4)μg/L, the hyaluronic acid levels were (178.6 ± 83.4)μg/L vs. (233.6 ± 81.6)μg/L, the collage typeⅣ levels were (6.6±1.4)μg/L vs. (7.4±1.3)μg/L, and the procollagen type III levels were (118.4±22.9) μg/L vs. (132.5±31.7)μg/L, respectively, in the two groups, with the difference being significant (P<0.05). Conclusion Fenofibrate could effectively reduce the blood lipid levels, improve vascular endothelial functions and reduce the index of serum liver fibrosis in patients with NAFLD and type 2 diabetes mellitus, which is worthy of clinical application.

Key words: Nonalcoholic fatty liver diseases, Type 2 diabetes mellitus, Fenofibrate, Vascular endothelial functions, Hepatic fibrosis

毛重山, 殷辉, 肖二辉, 张英英. 非诺贝特对非酒精性脂肪性肝病合并2型糖尿病患者血脂、血管内皮功能和肝纤维化指标的影响^*[J]. 实用肝脏病杂志, 2020, 23(1): 50-53.

Mao Chongshan, Yin Hui, Xiao Erhui, et al. Effects of fenofibrate on blood lipids, vascular endothelial functions and liver fibrosis in patients with nonalcoholic fatty liver disease and type 2 diabetes mellitus[J]. Journal of Practical Hepatology, 2020, 23(1): 50-53.

参考文献

[1] Iglay K, Hannachi H, Howie P J, et al. Prevalence and co-prevalence of comorbidities among patients with type 2 diabetes mellitus. Curr Med Res Opin, 2016, 32(7):1.
[2] Mccarty D J. Albiglutide for the treatment of type 2 diabetes mellitus. Nurse Pract, 2017, 42(2):10.
[3] Nie F, Wu D, Du H, et al. Serum klotho protein levels and their correlations with the progression of type 2 diabetes mellitus. J Diabetes Complicat, 2017, 31(3):594-598.
[4] 许勇,陶颖,苟小军. 非酒精性脂肪性肝病中医病因病机探析. 中华中医药学刊,2016,34(11):2586-2589.
[5] Hallsworth K, Thoma C, Hollingsworth K G, et al. Modified high-intensity interval training reduces liver fat and improves cardiac function in non-alcoholic fatty liver disease: a randomized controlled trial. Clin Sci, 2015, 129(12):1097-1105.
[6] 赵泽华,范建高. 2016年美国肝病年会非酒精性脂肪性肝病深度报道. 实用肝脏病杂志,2017,20(1):21-24.
[7] Zhang Z, Wang J, Wang H. Correlation of blood glucose, serum chemerin and insulin resistance with NAFLD in patients with type 2 diabetes mellitus. Exp Ther Med, 2018, 15(3):2936-2940.
[8] Fukuda T , Hamaguchi M , Kojima T , et al. The impact of non-alcoholic fatty liver disease on incident type 2 diabetes mellitus in non-overweight individuals. Liver Int, 2016, 36(2):275-283.
[9] 陈玉帅,王炳元,厉有名. 非酒精性脂肪性肝病与酒精性肝病2016研究进展. 中华肝脏病杂志, 2017, 25(3):181-186.
[10] Takahashi Y, Fukusato T. Histopathology of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. Metabolism, 2016, 65(8):1080-1086.
[11] Armstrong M J , Adams L A , Canbay A , et al. Extrahepatic complications of nonalcoholic fatty liver disease. Hepatology, 2016, 20(2):387-401.
[12] Pár A, Pár G. Advances in the pathogenesis of non alcoholic fatty liver disease. Orv Hetil, 2017, 158(23):882.
[13] Arab J P, Arrese M, Trauner M. Recent insights into the pathogenesis of nonalcoholic fatty liver disease. Annu Rev Pathol, 2018, 13(1):321-350.
[14]Hironori K , Guanliang C , Yinhua N , et al. Nonalcoholic fatty liver disease and insulin resistance: new insights and potential new treatments. Nutrients, 2017, 9(4):387.
[15] Yu J, Sharon M, Hu J, et al. The pathogenesis of nonalcoholic fatty liver disease: interplay between diet, gut microbiota, and genetic background. Gastroenterol Res Pract, 2016, 2016(6):1-13.
[16] Yaghoubi M , Jafari S , Sajedi B , et al. Comparison of fenofibrate and pioglitazone effects on patients with nonalcoholic fatty liver disease. Eur J Gastroenterol Hepatol, 2017, 29(12):1385.
[17] Smirnova E , Shulkina S , Loran E , et al. Relationship between skin blood flow regulation mechanisms and vascular endothelial growth factor in patients with metabolic syndrome. Clin Hemorheol Microcirc, 2017,25:1-14.
[18] Yao Y , Bao J , Lu Y , et al. Biomarkers of liver fibrosis detecting with electrochemical immunosensor on clinical serum. Sensor Actuat B Chem, 2016, 222(1):127-132.
[19] Nallagangula K S, Nagaraj S K, Venkataswamy L, et al. Liver fibrosis: a compilation on the biomarkers status and their significance during disease progression. Future Sci OA, 2018, 4(1):250.
[20] Yang X Z , Gen A W , Xian J C , et al. Diagnostic value of various noninvasive indexes in the diagnosis of chronic hepatic fibrosis. Eur Rev Med Pharmacol Sci, 2018, 22(2):479-485.

非诺贝特对非酒精性脂肪性肝病合并2型糖尿病患者血脂、血管内皮功能和肝纤维化指标的影响^*

Effects of fenofibrate on blood lipids, vascular endothelial functions and liver fibrosis in patients with nonalcoholic fatty liver disease and type 2 diabetes mellitus

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	杨可芷, 陆伟, 黄丹, 李秀芬, 王雁冰, 周新兰, 丁蓉蓉, 张占卿. γ-谷氨酰转肽酶/胆碱酯酶比值预测慢性乙型肝炎患者肝纤维化程度的效能评价^*[J]. 实用肝脏病杂志, 2020, 23(1): 14-17.
[2]	叶细容, 吕志红, 江峰, 解育新. 两种超声弹性成像技术诊断慢性乙型肝炎患者肝纤维化价值比较^*[J]. 实用肝脏病杂志, 2020, 23(1): 18-21.
[3]	陈丽丽, 符茂雄, 蒙绪标, 方其超. 空腹C肽评估NAFLD合并T2DM患者肝纤维化进展价值分析^*[J]. 实用肝脏病杂志, 2020, 23(1): 38-41.
[4]	柳健, 朱峰发, 唐娟. 非均匀性脂肪肝患者腹部超声表现和血脂变化特点^*[J]. 实用肝脏病杂志, 2020, 23(1): 42-45.
[5]	魏重操, 刘娜, 邢欣, 澹台新兴, 杨倩, 蒋潇洒, 王进海. 多烯磷脂酰胆碱联合二甲双胍治疗非酒精性脂肪性肝病患者疗效和安全性Meta分析[J]. 实用肝脏病杂志, 2020, 23(1): 46-49.
[6]	孙红菊, 王衍颜, 徐丛聪, 赵红. 硫普罗宁联合美他多辛治疗酒精性肝病患者疗效初步研究^*[J]. 实用肝脏病杂志, 2020, 23(1): 54-57.
[7]	骆庆玲, 周永健, 唐文娟, 首第文, 黄红丽, 徐豪明, 黄惠康, 何杰, 杜艳蕾, 阮焕梅, 陈慧婷, 曹创裕. 移植NAFLD患者和健康人粪菌对高脂饮食大鼠肠道菌群的影响^*[J]. 实用肝脏病杂志, 2020, 23(1): 134-137.
[8]	郭化磊, 卜理琳, 裴颖, 殷宏振, 黄峰. 化浊通瘀汤干预非酒精性脂肪性肝病大鼠血清肿瘤坏死因子-α和瘦素的变化^*[J]. 实用肝脏病杂志, 2020, 23(1): 138-141.
[9]	黄汉军, 鲁凤荣, 张灿. MRI联合血清维生素D预测慢性丙型肝炎患者肝纤维化临床价值探讨^*[J]. 实用肝脏病杂志, 2020, 23(1): 143-144.
[10]	. 肝纤维化诊断及治疗共识（2019年）[J]. 实用肝脏病杂志, 2019, 22(6): 793-803.
[11]	任俞霏, 陈小青, 孔维宗, 王迎春. 丹酚酸B对非酒精性脂肪性肝病细胞模型自噬功能的影响^*[J]. 实用肝脏病杂志, 2019, 22(6): 804-807.
[12]	闵峰, 黄文琪, 吴卫兵, 张丽, 范荣华. 慢性乙型肝炎患者血清脂肪细胞因子水平变化及其临床意义^*[J]. 实用肝脏病杂志, 2019, 22(6): 824-827.
[13]	吴海义, 陈建新. 四种诊断模型诊断乙型肝炎病毒携带者肝纤维化的效能分析^*[J]. 实用肝脏病杂志, 2019, 22(6): 832-835.
[14]	李颖怡, 郭翠芬, 章瑞南, 汪保灿, 潘勤, 汪余勤, 曹海霞, 范建高. ALDH2 rs671基因多态性与非酒精性脂肪性肝病相关性研究^*[J]. 实用肝脏病杂志, 2019, 22(6): 848-851.
[15]	邢欣, 魏重操, 周咪咪, 李小玲, 邓江, 鲁晓岚. 牛磺熊去氧胆酸与熊去氧胆酸治疗非酒精性脂肪性肝病患者疗效和安全性的Meta分析[J]. 实用肝脏病杂志, 2019, 22(6): 852-855.